Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 Clinical Trials

16 clinical trials for Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer — RECRUITING · PHASE3
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors — RECRUITING · PHASE2
• Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery — SUSPENDED · PHASE2
• Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer — COMPLETED · PHASE1
• Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
• Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma — COMPLETED · PHASE2
• Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers — WITHDRAWN · PHASE1
• IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer — COMPLETED · PHASE1

Refine this search